肝细胞癌患者肝移植术中及术后可溶性APO-1/Fas的检测及临床意义
摘要
目的:检测肝细胞癌(HCC)患者肝移植术中及术后血浆可溶性APO-1/Fas(sAPO-1/Fas)水平的变化。方法:对20例HCC患者分别于术前、无肝30 min、再灌注60 min、术后第3天4个时间点取血,血浆sAPO-1/Fas水平检测采用酶联免疫吸附ELISA法。结果:HCC患者移植术前血浆sAPO-1/Fas含量明显高于健康对照组。肝移植术中再灌注60 minsAPO-1/Fas水平显著升高,与术前相比差异有显著性。术后第3天血浆sAPO-1/Fas含量明显降低与健康对照组相比无统计学差异。结论:sAPO-1/Fas参与肝移植术中再灌注细胞凋亡。
出处
《陕西医学杂志》
CAS
2011年第11期1498-1499,共2页
Shaanxi Medical Journal
参考文献9
-
1Ambros JT, Herrero-Fresneda I, Borau OG, et al. Ischemic preconditioning in solid organ transplantation: from experimental to clinics [J]. Transpl Int, 2007,20 (3):219-229.
-
2史源,吕毅,刘昌,孟柯伟.DBcAMP对大鼠肝脏冷缺血再灌注损伤的保护作用[J].陕西医学杂志,2006,35(2):167-170. 被引量：2
-
3Montalvo-Jave EE, Escalante-Tattersfield T, Ortega- Salgado JA, et al. Factors in the pathophysiology of the liver ischemia-reperfusion injury [J]. J Surg Res, 2008 , 147 (1) : 153-159.
-
4张瑞峰,余海波.经导管肝动脉栓塞化疗对肝癌患者外周血淋巴细胞Fas的影响[J].陕西医学杂志,2008,37(10). 被引量：1
-
5Selzner M, Rudiger HA, Selzner N, et al. Transgenic mice overexpressing human Bcl-2 are resistant to hepatic ischemia and reperfusion [J]. J Hepatol, 2002, 36(2):218-225.
-
6Li B, Chen B, Zhang G,et al. Cell apoptosis and Fas gene expression in liver and renal tissues after ischemia- reperfusion injury in liver transplantation [ J ]. Transplant Proc, 2010,42 (5): 1550-1556.
-
7石银珍,陈梅,姜松,林明专.移植肾AR时病理诊断与细胞凋亡和Fas/FasL的表达[J].陕西医学杂志,2005,34(11):1395-1397. 被引量：1
-
8Wang Y, Liu Y, Han R, et al. Monitoring of CD95 and CD38 expression in peripheral blood T lymphocytes during active human cytomegalovirus infection after orthotopic liver transplantation [J]. J Gastroenterol Hepatol, 2010,25(1) :138-142.
-
9Nakajima H, Mizuta N, Fuiiwara I, et al. Blockade of the Fas/Fas ligand interaction suppresses hepatocyte apoptosis in ischemia-reperfusion rat liver [ J ]. Apoptosis, 2008,13 (8) : 1013-1021.
二级参考文献19
-
1Kamada N.A surgical experience with five hundred thirty transplantation in the rat.Surgery,1983; 93(1):64.
-
2Grynkiewicz G,Poenie M,Tsien RY.A new generation of Ca^2+ indicators with greatly improved fluorescence properties.J Biol Chem,1985; 260:3440.
-
3Churchill TA:Cheetham KM,Fuller BJ.Glycolysis and energy metabolism in rat liver during warm and cold ischemia:evidence of an activation of the regulatory enzyme phosphofructokinase.Cryobiology,1994; 31:441.
-
4Ursula R,Irith R,Anke F,et al.Oxygen free radical mediated injury to cultured rat hepatocytes during cold incubation in preservation solution.Hepatology,1997;26:353.
-
5Minor T,Isselhard W.Synthesis of high energy phosphates during cold ischemic rat liver preservation with gaseous oxygen.insufflation.Transplantation,1996;61:20.
-
6Minor T,Akbar S,Tolba R.Preservation of livers from non-heart-beating donors:modulation of cAMP signal and organ viability by glucagon.Transplantation Proceedings,1999 ; 31:1068.
-
7Emylio G,Constantin J,Henrique C.Transport of Cyclic AMP and Synthetic Analogs in the Perfused Rat Liver.Biochemical Pharmacology,2000; 59:1187.
-
8[1]Aoki T,Imamura H,Hasegawa K,et al.Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma.Arch Surg,2004,139(7):766-774.
-
9[2]Lau W Y,Ho S K,Yu S C,et al.Salvage surgery following downstaging of unreseetable hepatocellular carcinoma.Ann Surg,2004,240(2):299-305.
-
10[3]Rose D M,chapman W C,Brockenhrough A T,et al.Transcatheter arterial chemoembolization as primary treatment for hepatoeellular carcinoma.Am J Surg,1999,177(5):405-410.
-
1徐春华,于力克.可溶性Apo-1/Fas对结核性和恶性胸腔积液的鉴别诊断价值[J].中国基层医药,2012,19(15):2270-2272.
-
2梁启廉,潘达超,银正民,吴江,刘国勋,扬勤,谢杰荣,蔡良真,符有文.大肠癌患者化疗前后血清可溶性Apo-1/Fas水平变化及其临床意义[J].实用癌症杂志,2002,17(3):291-293.
-
3陶丽菊,王小超,陈诗强,揭旭日.非霍奇金淋巴瘤血清可溶性Apo-1/Fas的表达及意义[J].山东医药,2009,49(16):71-72. 被引量：1
-
4徐根波,卢兴国,罗吕宏,朱蕾.恶性肿瘤患者血浆和胸腹水可溶性Apo-1/Fas的检测及其临床意义[J].浙江大学学报（医学版）,2003,32(4):335-338. 被引量：6
-
5梁启廉,潘达超,银正民,刘国勋,扬勤,谢杰荣,蔡良真,符有文.化疗对肝癌患者血清可溶性Apo-1/Fas水平的影响及其临床意义[J].中国肿瘤临床,2002,29(4):234-236. 被引量：8
-
6胡奇志,方伟达,黄旭毅.中晚期胃癌化疗前后测定血清可溶性Apo-1/Fas水平的临床意义[J].实用肿瘤学杂志,2004,18(3):217-218.
-
7梁启廉,潘达超,银正民,刘国勋,扬勤,谢杰荣,蔡良真,符有文.血清可溶性Apo-1/Fas水平对监测胃癌生物学行为和预后的临床价值[J].癌症,2002,21(2):174-176. 被引量：10
-
8梁启廉,潘达超,银正民,吴江,刘国勋,扬勤,谢杰荣,蔡良真,符有文.食管癌患者化疗前后血清可溶性Apo-1/Fas水平变化及其临床意义[J].肿瘤,2002,22(3):233-235. 被引量：2
-
9侯文俊,王前,王巍炜,李高峰,杨秀梅.肺癌化疗前后血清可溶性Apo-Ⅰ/Fas水平变化及临床意义[J].中国民康医学,2008,20(19):2224-2225.
-
10胰、脾[J].中国医学文摘（肿瘤学）,2006,20(3):221-222.
